Follicular Lymphoma Education
Follicular lymphoma treatment is being transformed by bispecific antibodies, CAR-T cell therapy, and lenalidomide combinations — moving beyond traditional chemoimmunotherapy. Knowledge Med sessions help physicians navigate this evolving treatment landscape through interactive case simulations and real-time peer comparison.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing follicular lymphoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Determining when to initiate treatment vs active surveillance
- Choosing between chemoimmunotherapy, lenalidomide-rituximab, and novel agents
- Integrating bispecific antibodies (mosunetuzumab, epcoritamab) in relapsed disease
- Identifying candidates for CAR-T cell therapy and timing referral
What Sessions Cover
Knowledge Med FL sessions use interactive case simulations to address these topics and more.
- First-line treatment selection: bendamustine-rituximab vs lenalidomide-rituximab
- Bispecific antibodies in relapsed/refractory follicular lymphoma
- CAR-T cell therapy: patient selection, timing, and toxicity management
- Treatment-free intervals and watch-and-wait decision-making
Interactive FL Sessions
Case Simulations
Work through realistic follicular lymphoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key FL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a FL Session
Third-party, non-promotional follicular lymphoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session